Clinical Trials

BB3 is a small molecule with hepatocyte growth factor (HGF)-like activity that is entering Phase 3 clinical trials to limit delayed graft function in kidney transplant recipients, and also entering Phase 2 clinical trials in cardiac surgery patients who develop acute kidney injury. Prior studies in volunteers and patients have shown no safety concerns related to BB3.

BB3 Clinical Programs

  • Angion’s investigational drug BB3 is in Phase 3 for delayed graft function following kidney transplant. Read More
  • Angion’s investigational drug BB3 is in Phase 2 for acute kidney injury following open heart surgery using cardiopulmonary bypass. Read more